Get notified of page updates

Keyword: CDK inhibitor

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
How To Use XRAY ›
Search by Topic  ›
Submit an Article for Review
  ›
Showing 1 through 3 out of 3

Relevance: Medium-High

Most relevant for: People currently taking a CDK inhibitor

Guideline: FDA issues warning on CDK inhibitors

The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)

READ MORE  ›

Relevance: High

Most relevant for: People with metastatic, hormone-positive, Her2-negative breast cancer

Study: CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients

The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19) 

 

 

READ MORE  ›

Relevance: High

Most relevant for: People with metastatic, hormone-positive breast cancer

Study: The impact of palbociclib (Ibrance) on overall survival for metastatic breast cancer patients in the PALOMA-3 trial

The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)

READ MORE  ›